More Company News

Hutchison China MediTech

Updated Phase II savolitinib/Imfinzi combination data in advanced PRCC at ASCO GU 2020
10 Feb 2020Read More

Hutchison China MediTech

Exercise of underwriters’ over-allotment option for public ADS offering
06 Feb 2020Read More

Hutchison China MediTech

Pricing of $110m public offering of ADSs
23 Jan 2020Read More

Hutchison China MediTech

Proposed public offering of ADSs
22 Jan 2020Read More

Hutchison China MediTech

Surufatinib Phase III SANET-p study meets primary endpoint at interim analysis and will stop early
20 Jan 2020Read More

Hutchison China MediTech

Initiation of Phase II trial of Surufatinib in combination with Tuoyi in patients with advanced solid tumours
13 Jan 2020Read More

Hutchison China MediTech

Surufatinib NDA in non-pancreatic NET granted Priority Review in China
20 Dec 2019Read More

Hutchison China MediTech

Elunate (fruquintinib) included in the China NRDL
28 Nov 2019Read More

Hutchison China MediTech

Surufatinib granted FDA Orphan Drug Designation for Pancreatic NET
25 Nov 2019Read More

Hutchison China MediTech

NDA acceptance in China for surufatinib in non-pancreatic NET
11 Nov 2019Read More

1 2 3 4 5
Return to Hutchison China MediTech
© 2019-20 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).